Subscribe To
ESALY / Dow Jones Newswires: Eisai shares sink after Japan regulators seek more data for review of Alzheimer's drug
ESALY News
By PRNewsWire
March 23, 2023
Eisai to Present Research from Oncology Portfolio at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
Study Findings in Patients with Recurrent or Advanced Endometrial Carcinoma Who Were Rechallenged With Platinum Chemotherapy Will Be Featured in an Or more_horizontal
By CNBC
March 6, 2023
FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July
Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval. more_horizontal
By CNBC
February 17, 2023
Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage
Even if the FDA grants full approval of the Alzheimer's treatment Leqembi, the rollout of the treatment will take years. more_horizontal
By Yahoo Finance
February 13, 2023
Alzheimer's drug Leqembi: Eisai U.S. president
Eisai U.S. President Ivan Cheung joins Yahoo Finance Live to discuss the latest news surrounding Alzheimer's treatment with Leqembi. more_horizontal
By Seeking Alpha
February 6, 2023
Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Call Transcript
Eisai Co., Ltd. (OTCPK:ESALF) Q3 2022 Earnings Conference Call February 6, 2023 3:15 AM ET Company Participants Tatsuyuki Yasuno - Senior Vice Preside more_horizontal
By Reuters
January 6, 2023
Eisai files for full FDA approval for Alzheimer's drug Leqembi
Japanese drugmaker Eisai Co Ltd said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its more_horizontal
By CNBC Television
January 6, 2023
CNBC Exclusive: Eisai U.S. CEO on Alzheimer's drug approval
CNBC's Meg Tirrell talks to Ivan Cheung, Eisai U.S. CEO on the company's Alzheimer's drug receiving approval from the FDA today. With CNBC's Tyler Mat more_horizontal
By Yahoo Finance
January 6, 2023
FDA approves Biogen-Eisai Alzheimer's drug, China in talks to make Pfizer Paxlovid generic
Yahoo Finance health care reporter Anjalee Khemlani highlights the progress on Biogen-Eisai's collaborative Alzheimer's treatment drug and China's pla more_horizontal